A Parallel Group, Randomized, Open-label Study to Investigate the Effect of the Intravaginally Administered Antimycotic Miconazole, Antibiotic Clindamycin, Spermicide Nonoxynol-9, or Co-usage of Tampons on 3 Consecutive Days on the Pharmacokinetics of Anastrozole and Levonorgestrel Released From an Intra-vaginal Ring in Healthy Young Women

To investigate the pharmacokinetic effect of a vaginally administered antimycotic (miconazole), antibiotic (clindamycin), spermicide (nonoxynol-9) or the concomitant use of tampons during the use of an intravaginal ring releasing anastrozole and levonorgestrel

开始日期2015-09-15

申办/合作机构

Bayer AG

NCT01593124 / Completed临床2期IIT

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

This study investigates the response of vaginal and cervical tissue after exposure to three vaginal products: hydroxyethyl cellulose (HEC) placebo, nonoxynol-9 (N9) and imiquimod (IMQ) cream.

开始日期2012-05-01

申办/合作机构

Contraception Research and Development

NCT00000926 / Completed临床3期IIT

Phase III Nonoxynol-9 and HIV Infection

The purpose of this study is to see if nonoxynol-9 (N-9) gel used in the vagina can prevent the spread of HIV.
Most of the people with HIV in the world today live in southern Africa. Because this population is not likely to use condoms, an HIV-prevention method that women can control is needed. N-9 used in the vagina may help prevent the spread of HIV and other sexually transmitted diseases.

开始日期-

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与壬苯醇醚-9 相关的临床结果

登录后查看更多信息

100 项与壬苯醇醚-9 相关的转化医学

登录后查看更多信息

100 项与壬苯醇醚-9 相关的专利（医药）

登录后查看更多信息

621

项与壬苯醇醚-9 相关的文献（医药）

2025-01-01·ENVIRONMENTAL POLLUTION

Surfactants can compete with microplastics for surfaces using adhesives as substrates for microplastic sequestration

Article

作者: Love, Brian J ; Zimmerman, Paul M. ; Love, Brian J. ; Lawal, Tolulope ; Lawal, Tolulope D ; Zimmerman, Paul M ; Josephs, Griffin ; Jugovic, Timothy

Experimental efforts supplemented by modeling gauged whether common additives found in soaps and laundry detergents interfered with polyacrylate adhesive-based capture of microplastics. On the experimental front, poly(2-ethylhexyl acrylate) (PEHA) samples were evaluated using gravimetric analysis, probe tack, and functional assessments of adhesive-coated glass slides immersed into DI water solutions containing both microparticles and additives (solvents, softeners, and non-ionic surfactants). Nylon-6 spheres and polyethylene terephthalate microplastics were chosen for adsorption using a count-based method by ImageJ imaging analysis. Molecular dynamics computations simulated 2-ethyl-hexylacrylate (2-EHA) adhesive and microplastic interactions in the presence of water, citrate, glycerol and tergitol detergent additives. The experimental work showed that fewer microplastics were collected when tergitol was added and was in line with lower experimental Work of Adhesion (WoAaq) results for nylon and PETE (94.5% and 54.5% reductions respectively). Computational results also confirmed lower adhesion in the presence of tergitol. The experiments also showed that the adhesive swelled while equilibrating in additive solutions. Models suggested that tergitol most negatively impacted particle binding through a competitive "blocking" of the adhesive substrate while the other additives were less conclusive about potential interferences based on competitive binding.

2024-07-22·BIOTECHNIQUES

Transitioning from Triton X-100 to Tergitol 15-S-9: impacts on diagnostic assays using viral PCR sample solution

Article

作者: Zorzoli, Azul ; Sakka, Noha El ; Bennet-Slater, Susan ; Gunson, Rory ; Tait-Burkard, Christine ; Nicholson, Scott ; Daniels, Alison ; MacLean, Alasdair ; Hughes, Stephen ; Templeton, Kate

In 2019, the European Union banned Triton X-100, a detergent widely used in laboratory diagnostics, including the Viral PCR Sample Solution (VPSS), and urged manufacturers to find environmentally sustainable alternatives. Tergitol 15-S-9 (VPSS2) has been proposed as an alternative surfactant. This multicenter study evaluated the effectiveness of VPSS2, a Tergitol-based viral solution, as a replacement for VPSS. Our results show the equivalent performance of VPSS2 to VPSS for nucleic acid extraction and viral stability over time at different temperatures. The new VPSS formulation was also tested against external quality assurance panels and clinical samples. The results of this work support adopting this modified viral PCR sample solution to replace Triton X-100-containing viral transport solutions.

2024-01-01·Food chemistry

Cloud point extraction of carbendazim fungicide from strawberry samples and amperometric detection with boron doped diamond

Article

作者: Caixeta-Neta, Antonia ; Ribeiro, Gabriela C ; Andrade, Leonardo S ; de Amorim, Kamila P

The cloud point extraction (Tergitol® surfactant) method was used for the first time to extract and preconcentrate the fungicide carbendazim (CBZ) from strawberry samples, while electrochemical detection (boron doped diamond electrode) in association with high performance liquid chromatography (HPLC-EC) was used for the determination of CBZ. The variables of bath temperature, ultrasonic stirring time, mass of NaCl and amount of surfactant were investigated using a 2⁴ full factorial design. Limits of detection (LOD, S/N = 3) and quantification (LOQ) of 3.42 × 10^-8 mol/L (or 6.54 µg/L) and 6.84 × 10^-8 mol/L (or 13.1 µg/L), respectively, were obtained for the CPE processes, considering the value of the preconcentration factor obtained (9.12). The method was validated based on linearity, intra-day and inter-day recovery tests, accuracy and precision. The proposed method was applied to strawberry samples from local commercial establishments and different procedures for washing and sanitizing strawberry fruits were also evaluated.

项与壬苯醇醚-9 相关的新闻（医药）

2023-05-09

·蒲公英Ouryao

160个品种和80个技术方法→国家药品标准提高工作通知来了

转自：药典委员会整理：wangxinglai20042023年05月09日，国家药典委员会发布了《关于做好2023年度国家药品标准提高工作的通知》，本次标准提高共计涉及160个品种和80个技术方法。2023年国家标准提高重点内容1、涉及品种：苍术、沉香、川楝子、大黄、淡豆豉、甘草、炙甘草、枸杞子、广藿香、何首乌、制何首乌、花椒、降香、沉香化滞丸、半夏露颗粒、宽胸利膈丸、润肠丸(浓缩丸/水蜜丸) 、五加参归芪精、宝宝乐、小儿感冒颗粒（茶，口服液）、小儿吐泻宁散、阿拉坦五味丸、澳泰乐颗粒、苁黄补肾丸、二天油、风湿药丸、复方矮地茶片、复方板蓝根颗粒、复方荆芥熏洗剂、脑栓通胶囊、清热祛湿颗粒、麝香牛黄丸、麝香通心滴丸盐酸托莫西汀、盐酸托莫西汀胶囊、盐酸托莫西汀口服溶液、磷酸铝凝胶、壬苯醇醚、注射用米卡芬净钠、头孢呋辛酯、头孢呋辛酯胶囊、磺胺嘧啶锌、磺胺嘧啶锌软膏、聚乙二醇化重组人粒细胞刺激因子注射液、聚乙二醇化人生长激素注射液、利妥昔单抗、英夫利西单抗、曲妥珠单抗、贝伐珠单抗、四价流感病毒裂解疫苗、I型III型脊髓灰质炎减毒活疫苗糖丸(人二倍体细胞) 、双价人乳头瘤病毒疫苗(毕赤酵母) 、冻干b型流感嗜血杆菌结合疫苗、13价肺炎球菌多糖结合疫苗、环拉酸钠、混合脂肪酸甘油酯（硬脂）、聚甲丙烯酸铵酯Ⅰ、聚甲丙烯酸铵酯Ⅱ、磷酸钙、石蜡、甜菊糖苷、无水亚硫酸钠； 2、涉及通用技术方法：动物药来源及拉丁名规范研究、显微鉴别方法学研究、药材和饮片填平补齐（完善标准）、植物药来源及拉丁名规范研究、性状显微鉴别项梳理研究Ⅲ、高风险重金属及有害元素残留药材及饮片风险评估、中成药标准中乌头和马钱子类限量检查和含量测定方法及指导原则研究、细胞治疗产品总论、单克隆抗体Fc段介导效应功能评价方法研究、注射用人白介素-11生物学活性测定质量标准研究、免疫电泳法电泳缓冲液替代研究、采用体外效价测定方法替代动物体内试验用于生物制品质量控制的相关技术指导原则、间充质干细胞生物学效力检测方法的研究与开发、抗体类产品中蛋白A残留测定法、基于Nb2-11细胞增殖的人生长激素生物学活性测定方法研究、无细胞百白破联合疫苗有效组分鉴别试验(多重竞争抑制法) 、天平与称量指导原则的增订、水活度测定法的增订、0441核磁共振波谱法的修订、0431质谱法的修订、0982粒度和粒度分布测定法激光光散射法的修订、原子量表的规范化研究、蛋白质组学分析方法及应用指导原则的研究、0931溶出度与释放度测定法浸没池法的建立、溶液电导率测定法的增订、光学显微镜法的增订、基于红外光谱法和拉曼光谱法的0981结晶性检查法的修订与应用研究、近红外光谱法的修订、1001聚合酶链式反应法的修订、9014微粒制剂指导原则修订、0105眼用制剂通则修订、0127洗剂通则修订、微生物MALDI-TOFMS菌种鉴定技术指导原则的研究、药品微生物快速检测技术指导原则的研究、药用辅料粉体流动性测定—剪切池法、药用辅料熔融黏度测定法、充填剂转矩流变性的表征及评价方法研究、复杂药用辅料关键质量属性指标的定量核磁控制研究、中国药典药用辅料标准残留溶剂控制相关标准的研究、中国药典药用辅料标准元素杂质控制相关标准的研究、药品包装系统密封性研究指导原则、药品包装系统密封性检查法、药包材检验规则指导原则、预灌封注射器相关通则、预灌封注射器通则配套通用检测方法、笔式注射器相关通则、《药包材生物学评价与试验选择指导原则》配套检查法、药品包装用橡胶密封件相关通则、药品包装用橡胶密封件配套通用检测方法、《药包材中金属元素金属离子测定法》起草、《药包材不溶性微粒测定法》起草、《药包材溶出物测定法》起草、药品包装用玻璃容器相关通则。3、通知原文各有关单位：按照国家药典委员会《药品标准制修订研究课题管理办法》（以下简称“管理办法”），经公开征集课题建议及承担单位、组织专业委员会及专家组审议、网上公示、药典委审核等程序，确定了2023年度国家药品标准提高任务，具体如下：为确保2023年度国家药品标准提高工作顺利开展，现将有关事项通知如下：一、严格执行管理办法，按照《国家药品标准制修订研究课题合同书》及其附件确定的工作任务、研究目标、考核指标、经费预算，确保工作进度，确保工作质量。二、起草单位、复核单位和牵头单位按照经费性质分别填报相应的电子版和纸质版合同书（详见附件3、4），其中，由国家药典委员会拨付课题经费的承担单位填写A类合同（附件3），由承担单位自行解决课题经费的填写B类合同（附件4）。请自本通知发布之日起十五日内，将电子版合同书按照类别发送至相应处室联系人邮箱。待审核通过并告知你单位后，再请将加盖本单位公章的纸质版合同书按照类别寄送至相应处室。我委签署合同后，将分送至相关单位。各处室联系人及方式如下：中药处：赵宇新（010－67079523；zy@chp.org.cn）化学药品处：王志军（010－67079559；hybztg@chp.org.cn）生物制品处：陈慧毅（010－67079527；chenhuiyi@chp.org.cn）通则辅料包材处：朱冉（010－67079581；chp4@chp.org.cn）通讯地址：北京市东城区法华南里11号楼（邮编：100061）点击阅读原文下载附件

疫苗细胞疗法

2013-07-24

·BioSpace

Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora&#0174 Non-hormonal Contraceptive Gel

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today! DURHAM, N.C, July 24, 2013 /PRNewswire-iReach/ -- Health Decisions, Inc., the leading clinical research organization focusing on efficiency in execution of clinical development, today announced early completion of enrollment for a 3,384-subject phase III registration study of Evofem LLC's Amphora® nonhormonal contraceptive gel. (Photo: ) The global trial compares Amphora to Conceptrol®, the brand name of nonoxynol-9, and the only spermicidal gel currently approved by the FDA. "We are pleased that our focus on efficiency enabled us to enroll this important study well ahead of schedule," said Health Decisions CEO Michael Rosenberg, MD, MPH. "Our ability to use technology to enroll studies faster and to better retain subjects enables us to generate information more quickly than industry norms. This study is a good example and will provide Evofem with an earlier market entry than would otherwise have been possible." Dr. Rosenberg attributed successful enrollment of the Amphora study to the power of Agile Clinical Development, Health Decisions' award-winning, technology-leveraged approach to running clinical trials based on immediate, actionable information from the field. "Our approach and supporting technologies enable us to enroll over 80% of our studies on time or early when the rest of the industry is enrolling about 80% late," Rosenberg said. "In the Amphora study, our integrated adaptive enrollment techniques enabled us to enroll almost 3,400 subjects three to four times faster than previous trials of similar products that enrolled less than half as many subjects." Health Decisions enrolled the Amphora study at a rate of 125 subjects per month compared with 38 subjects per month and 30 subjects per month for previous large studies of similar products. One such study with a target enrollment of 1,800 subjects was terminated without meeting its enrollment goals. "We are very pleased with the progress on the development of Amphora," said Tommy G. Thompson, former US Health and Human Services Secretary, and Chairman of the Evofem Board of Directors. "Evofem is committed to providing women around the world with greater contraceptive choice and we expect Amphora to fill a critical gap in the market as an inexpensive, easy-to-use product that is woman-controlled and used only when necessary, on-demand." Dr. Rosenberg also noted, "Our integrated adaptive monitoring approach works on the same real-time principles as adaptive enrollment and also provided striking benefits in the Amphora trial, simultaneously reducing monitoring costs and increasing data quality." Health Decisions won the prestigious 2013 CIO 100 Award for its innovative adaptive monitoring technology. About Health Decisions Health Decisions is the leading clinical research organization (CRO) in Agile Clinical Development, providing proactive trial management based on real-time actionable information, enabling decisions that accelerate clinical studies and programs. For the drug and device industries, Agile Clinical Development provides a way to get new products to market faster and at lower cost. For the public, it means earlier access to improved treatments and diagnostics at more affordable prices. Founded in 1989, Health Decisions has conducted a range of successful clinical trials involving tens of thousands of patients, consistently reducing sponsors' financial risk and time to market. Privately held, Health Decisions is headquartered in Durham, NC and operates on all five continents. About Evofem Evofem LLC is a privately held biotechnology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception, and the prevention of sexually transmitted infections. In February 2013, Evofem entered into a strategic alliance with WomanCare Global, a nonprofit organization whose mission is to provide access to quality, affordable, women's healthcare products through a sustainable supply chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, WomanCare Global provides sales, marketing and global distribution support to Evofem's products. News distributed by PR Newswire iReach: SOURCE Health Decisions Help employers find you! Check out all the jobs and post your resume.

100 项与壬苯醇醚-9 相关的药物交易

登录后查看更多信息